Monitoring of Oral Anticoagulation by an Amidolytic Factor X Assay

B Lämmle; H Bounameaux; G A Marbet; R Eichlisberger; F Duckert

doi:10.1055/s-0038-1650107

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1980; 44(03): 150-153
DOI: 10.1055/s-0038-1650107

Original Article

Schattauer GmbH Stuttgart

Monitoring of Oral Anticoagulation by an Amidolytic Factor X Assay

A Long-Term Study in 42 Patients

B Lämmle

The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basle, Switzerland

,

H Bounameaux

The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basle, Switzerland

,

G A Marbet

The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basle, Switzerland

,

R Eichlisberger

The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basle, Switzerland

,

F Duckert

The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basle, Switzerland

› Author Affiliations

Abstract

PDF Download

Summary

The validity of the amidolytic Factor X assay for the control of long term oral anticoagulation (OA) was investigated in 42 patients randomized into 2 groups; PT group (anticoagulant dosage according to PT) and F. X group (anticoagulant dosage based on F. X). An independent expert's dosage according to F. X served for analysis in the former group. In the F. X group the F. X based dosage was considered valid only when not differing by more than 15% from the expert's PT based dosage.

Confirming the good correlation between PT and F. X the study further demonstrates that the changes from one control to the next one, ΔPT and ΔF. X, too, are significantly correlated (r = 0.58, p & 0.001, n = 217). In over one third of the periods the dosage proposals based on PT and F. X were identical and differed by more than 15% in only 12/217 instances.

Our results justify a large trial on the control of OA by the amidolytic F. X assay.

Key words

Oral anticoagulation - Monitoring - Factor X - Amidolytic assay - Prothrombin time - Chromogenic substrate

PDF (780 kb)

References

References
1 Bergstroem K, Egberg N. Determination of Vitamin K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates. Thromb Res 1978; 12: 531-547
2 Lämmle B, Eichlisberger R, Haenni L, Bounameaux H, Marbet GA, Duckert F. Kontrolle der oralen Antikoagulation. Vergleich zwischen Quick- und kolorimetrischer Faktor X-Bestimmung bei 107 Patienten. Schweiz med Wschr 1979; 109: 1115-1119
3 Mibashan RS, Scully MF, Birch AJ, Thumpston JK, Mac Gregor IR, Kakkar VV. Automated control of coumarin therapy by chromogenic Factor X assay (Abstract). Thromb Haemostas 1979; 42: 291
4 Famodu AA, Ingram GI C, Darby SC. Anticoagulant Control with chromogenic measurements of Factor X and VII (Abstract). Thromb Haemostas 1979; 42: 292
5 Erskine JG, Walker ID, Davidson JF. Maintenance control of oral anticoagulant therapy by a chromogenic substrate assay for factor X. J Clin Pathol 1980; 33: 445-448
6 Aurell L, Friberger P, Karlsson G, Cleason G. A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb Res 1977; 11: 595-609
7 Kabi Diagnostica S-2222 Determination of factor X in plasma. Laboratory Instruction 1977